|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. Our most advanced product candidate, AM-101, is in Phase 3 clinical development for acute inner ear tinnitus under a special protocol assessment, or SPA, from the FDA. In two recently completed Phase 2 clinical trials, AM-101 demonstrated a favorable safety profile and statistically significant improvement in tinnitus loudness and other patient reported outcomes. We are also developing AM-111 for acute inner ear hearing loss, and we expect to begin Phase 3 clinical development in the fourth quarter of 2014. We expect to have top-line Phase 3 clinical data for AM-101 and AM-111 in early 2016 and late 2016, respectively. Both acute inner ear tinnitus and hearing loss are conditions for which there is high unmet medical need, and we believe that we have the potential to be the first to market in these indications. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
13 |
Founded: |
2003 |
|
| Contact Information |
| Address: |
Bahnhofstrasse 21, 6300 Zug, Switzerland |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -18.7 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
EARS |
| Shares (millions): |
9.4 |
| Price Range: |
$6.00 - $6.00 |
| Est.$ Volume |
$ 56.4 mil |
| Manager / Joint Managers |
Jefferies/ Leerink Partners |
| Co Managers |
JMP Securities/ Needham & Company |
| Expected to Trade |
8/6/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
